# Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients

> **NCT01649427** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 73 (actual)

## Conditions studied

- Pharmacokinetics Study in de Novo Kidney Transplantation

## Interventions

- **DRUG:** Prograf
- **DRUG:** Tacrolimus Hexal

## Key facts

- **NCT ID:** NCT01649427
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-17
- **Primary completion:** 2015-08-20
- **Final completion:** 2015-08-20
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01649427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01649427, "Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01649427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*